| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6259791 | Behavioural Brain Research | 2011 | 5 Pages |
Schizophrenia is a severe mental illness characterized by positive and negative symptoms and cognitive deficits. Reduction of glutamatergic neurotransmission by NMDA receptor antagonists mimics symptoms of schizophrenia. Modeling social interaction and cognitive impairment in animals can be of great benefit in the effort to develop novel treatments for negative and cognitive symptoms of schizophrenia. Studies have demonstrated that these behavioral changes are, in some cases, sensitive to remediation by antipsychotic drugs. The zebrafish has been proposed as a candidate to study the in vivo effects of several drugs and to discover new pharmacological targets. In the current study we investigated the ability of antipsychotic drugs to reverse schizophrenia-like symptoms produced by the NMDA receptor antagonist MK-801. Results showed that MK-801 (5 μM) given pre-training hindered memory formation while both atypical antipsychotics sulpiride (250 μM) and olanzapine (50 μM) improved MK-801-induced amnesia. The same change was observed in the social interaction task, where atypical antipsychotics reversed the MK-801-induced social interaction deficit whereas the typical antipsychotic haloperidol (9 μM) was ineffective to reverse those behavioral deficits. Therefore, MK-801-treated zebrafish showed some behavioral features observed in schizophrenia, such as cognitive and social interaction deficits, which were reverted by current available atypical drugs.
⺠MK-801 given pre-training hindered memory formation. ⺠Atypical antipsychotics, sulpiride and olanzapine, improved MK-801-induced amnesia. ⺠MK-801 produced social interaction deficit. ⺠Atypical antipsychotics reversed the MK-801-induced social interaction deficit.
